A new study sheds light on the elusive nature of fatigue in multiple sclerosis and its implications for treatment. The findings provide a comprehensive review of current challenges in defining, measuring, and treating MS-related fatigue, offering new insights and directions for future research.

The study highlights the multidimensional nature of fatigue, emphasizing the ongoing struggle to define it accurately and measure it effectively. Kessler Foundation researchers identified more than 250 scales used to assess fatigue but noted significant content validity issues, raising questions about their effectiveness.

Fatigue affects up to 90 percent of individuals with MS, significantly affecting their daily lives. Despite its prevalence, defining fatigue remains challenging because of its subjective and multifaceted nature. The study reviews historical and contemporary definitions of fatigue, critiques existing measurement tools for their lack of clarity and consistency, and explores the subjective nature of fatigue and its correlation with other symptoms such as depression, pain, and cognitive complaints. The researchers examined the brain's role in fatigue, proposing that disruptions in the cortico-striato-thalamo-cortical loop contribute to central fatigue. 

The study examined both pharmacological and nonpharmacological treatments for fatigue in MS. Pharmacological treatments, such as amantadine, modafinil, and methylphenidate, have shown limited effectiveness. In contrast, the article also explores nonpharmacological treatments for fatigue, such as cognitive-behavioral therapy and exercise, which have shown moderate to large effects in reducing fatigue symptoms. Additionally, the potential of novel approaches involving the brain's reward system is mentioned, suggesting that motivational incentives could play a crucial role in managing fatigue in MS patients.

The findings were published in the Journal of Neurology.